Mike Lobosco

Executive Director -global Commercial & Medical Affairs Field Effectiveness at Sarepta Therapeutics

Mike Lobosco has a diverse work experience in the pharmaceutical and biotech industry. Mike has held various roles at different companies throughout their career. Mike started at Sanofi in 2000 as a Sales Professional and gradually worked their way up to become a Manager, Commercial Capabilities. Mike played a key role in aligning brand strategy with field execution and integrating Genzyme products after Sanofi's acquisition. Mike also developed and delivered training materials for national and regional sales meetings. In 2012, they joined Millennium Pharmaceuticals as a Senior Manager Training Development, where they focused on training and development initiatives. Later, they became an Associate Director of Oncology Training & Communications, overseeing launch plans and ensuring sales development strategies aligned with marketing initiatives. Mike then moved to Takeda Oncology in 2016 and held various leadership positions, including Director of US Oncology Sales Strategy and Brand Head of US Marketing for VELCADE. In their current role at Sarepta Therapeutics, Mike serves as the Executive Director of Global Commercial & Medical Affairs Field Effectiveness, responsible for driving field effectiveness strategies.

Mike Lobosco obtained their Bachelor of Science degree in Biochemistry from Stony Brook University. Mike later completed their Master of Business Administration (MBA) with a focus on Pharmaceutical Marketing at the Erivan K. Haub School of Business at Saint Joseph's University. In 2012, they also received a LEAN Six Sigma Green Belt Certification from the Institute for Healthcare Quality Research and Education.

Links

Previous companies

MILLENNIUM PHARMACEUTICALS, INC. logo
Sanofi logo
Takeda Oncology logo

Timeline

  • Executive Director -global Commercial & Medical Affairs Field Effectiveness

    March, 2023 - present

  • Senior Director - Commercial & Medical Affairs Field Effectiveness

    November, 2020